Progressive supranuclear palsy (PSP) is a rapidly progressive neurodegenerative disorder with clinicopathologic heterogeneity and without any therapies. Genetic studies can be instrumental in the identification of the molecular pathophysiology underlying PSP risk and its heterogeneity, which may enable discovery of therapeutic targets. Until recently, H1 haplotype of MAPT, encoding tau, was the strongest genetic risk factor for PSP. A new PSP genome-wide association study (GWAS) identified six additional loci. The effective translation of these findings to therapy requires identification of he disease gene, the functional variants and their mechanism of action. These goals cannot be achieved by the disease GWAS alone and require alternative, powerful and mechanistic approaches. The current proposal aims to close this knowledge gap by joint analysis of the whole transcriptome and quantitative neuropathology measures in a well- characterized autopsied PSP cohort with existing GWAS data. Our long-term goal is to uncover the pathophysiology of PSP and the molecular substrates of its subtypes that will ultimately lead to drug discoveries. Given the clinicopathological overlap between PSP and other tauopathies, our proposal is expected to impact a wide range of neurodegenerative disorders and generate novel therapeutic avenues. Our central hypothesis, is that many PSP variants confer risk by regulating brain gene expression. Further, differential transcriptional regulation may underlie the heterogeneity in PSP. Our preliminary data identified brain transcript associations for some of the top PSP GWAS variants supporting our hypothesis. In our Brain Bank, we have access to nearly 500 brain samples from autopsied PSP subjects with existing GWAS, ~400 of which have typical and ~100 with atypical clinicopathology. All subjects have clinical data and detailed quantitative neuropathology measures. Our objective is to obtain brain transcriptome measurements in this unique cohort, which will be analyzed jointly with quantitative neuropathology measures to identify functional variants underlying PSP risk, its clinicopathological heterogeneity and to discover the mechanism of action of these variants. The expected outcomes of our specific aims are: 1) To identify a) genetic variants that influence gene expression in PSP brains, b) transcript level differences between subtypes of PSP that are not simply due to aging;2) To discover a) genetic factors that influence both neuropathology and gene expression in PSP;b) transcripts that correlate with neuropathology;3) To uncover the mechanism of transcriptional regulation in PSP by a) next-generation RNA sequencing of 200 select PSP brain samples;b) translational in- vitro studies. Results from all aims will be compared with the PSP disease GWAS. The overall knowledge will nominate genes and their transcriptional changes as novel disease mechanisms in PSP. These molecular mechanisms will constitute modifiable drug targets, which will impact PSP and other related neurodegenerative diseases.

Public Health Relevance

The proposed research is relevant to public health because uncovering the genetic risk factors of Progressive Supranuclear Palsy (PSP) is fundamental for the understanding of its formation, may provide progress in its prediction, prevention and potential drug targets for the cure of this rapidly progressive, currently incurable disease, and also possibly of other related neurodegenerative diseases. Our proposal is aimed at the discovery of functional PSP risk variants that influence gene expression and brain PSP pathology, by leveraging existing genome-wide association studies and highly informative autopsied cohorts with rich data. Thus, the proposed research is relevant to NIH's mission to develop fundamental discoveries and resources to improve public health, as these studies are expected to have a significant impact in research on PSP risk and pathology and will constitute an important shared resource with significant utility for projects and researchers beyond the scope of this proposal.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS080820-01A1
Application #
8581094
Study Section
Neurological, Aging and Musculoskeletal Epidemiology (NAME)
Program Officer
Sieber, Beth-Anne
Project Start
2013-07-15
Project End
2018-06-30
Budget Start
2013-07-15
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$342,344
Indirect Cost
$123,594
Name
Mayo Clinic Jacksonville
Department
Type
DUNS #
153223151
City
Jacksonville
State
FL
Country
United States
Zip Code
32224
Medway, Christopher W; Abdul-Hay, Samer; Mims, Tynickwa et al. (2014) ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. Mol Neurodegener 9:11
Carrasquillo, Minerva M; Khan, Qurat ul Ain; Murray, Melissa E et al. (2014) Late-onset Alzheimer disease genetic variants in posterior cortical atrophy and posterior AD. Neurology 82:1455-62
Pedraza, Otto; Allen, Mariet; Jennette, Kyle et al. (2014) Evaluation of memory endophenotypes for association with CLU, CR1, and PICALM variants in black and white subjects. Alzheimers Dement 10:205-13
Salloway, Stephen; Sperling, Reisa; Fox, Nick C et al. (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370:322-33